1. Market Research
  2. > Pharmaceutical
  3. > Drug Discovery and Development Market Trends
  4. > Latin American Contract Research Organization Market : Lower Cost of Conducting Clinical Trials Will Drive Growth

Key Findings—LATAM

Clinical Development Spending
•Since 2008, LATAM (Latin America) has been one of the fastest growing pharmaceutical markets in the world. Brazil is expected to become the fourth largest drug market by 2016, behind the United States, China, and Japan. The main drivers for market growth are generic drugs manufactured by local pharmaceutical companies and biosimilars manufactured both by multinational and local pharmaceutical companies.
•In 2013, the LATAM clinical trials market size was $ x million and is expected to reach $ x million in 2019. The LATAM clinical trials outsourcing market size was $ x million in 2013 and is expected to reach $ x million in 2019.

MNC and Local Pharmaceutical Companies
•Pharma MNCs constituted x % of clinical trial spending in 2013. However, local trials will grow in terms of number of trials conducted and expenditure per trial. When compared to local trials conducted a few years ago, which usually involved incremental innovation, biologic and biosimilar development will have larger investments and more complex protocols.

Global and Local Trials
•In LATAM, global trials accounted for x % of the market revenue. Nevertheless, local trials are expected to increase in share over the next x years. In Brazil and Argentina, the main target is biosimilar development. In Mexico, local trials may increase due to regulatory requirements which state that clinical studies for biocomparable products must be conducted locally.

Clinical Trials Phase Breakdown
•In LATAM, the largest share of trials conducted were Phase III trials. In 2013, Phase III accounted for x % of revenue in LATAM.
•In Late Phase trials, pharmacovigilance represents the largest share. However, health economics and outcomes research will have the fastest growth in the next x years.
•Data management services represent x % of the cost of clinical trials. Biostatistics represent x %, while central laboratory services represent x % of the cost of clinical trials.

Competitors Analysis
•MNC contract research organizations (CROs) dominate the LATAM market, mainly providing services to pharma MNCs. Price is the key barrier to more interaction between local pharmaceutical companies and MNC CROs.
•Though local CROs provide lower price, their service quality is low.

Clinical Development—Market Trends
•Clinical developments made by local pharmaceutical companies are the main drivers for the clinical trials market, mainly in Brazil and Argentina.
•Biologics and biosimilars currently account for a combined x % of trials conducted in Brazil, x % in Mexico, and x % in Argentina. In the next few years, biologics and biosimilars are expected to surpass x % in number of trials.
•Key restraints for growth in Argentina and Brazil are related to regulatory issues such as long protocol approval timelines. In Brazil, because of bottlenecks in submission and approval processes from Anvisa, approval takes x months. In Argentina, a protocol takes an average of x months for approval.
•In Brazil, the public funding programs fostering local pharmaceutical research and development (R&D) are expected to continue. Local drug development is being used as a strategy to reduce public healthcare expenditure in the procurement of high-cost imported drugs.

Outsourced Clinical Trials
•Outsourcing is becoming more frequent as protocols are more complex and recruitment is more specific regarding inclusion and exclusion criteria.
•Pharma MNCs tend to outsource about x % of their trials (number of trials) either in fully outsourced or in a function-to-function model. Local pharmaceutical companies have lower outsourcing rates; the rates are x % in Mexico, x % in Argentina, and x % in Brazil.
•Phase I and II trials have the lowest share of outsourcing, as many early phase studies in Latin America are performed by public research institutes and universities that do not outsource trials.
•Phase III trials represent the largest market for outsourced revenues, accounting for $ x million in 2013 and reaching $ x million in 2019.
•Data management is a highly outsourced service, mostly performed by MNC CROs which send data to be analyzed abroad due to lower costs and larger availability of skilled professionals. Few small local companies provide data management in LATAM, but are more focused on serving local pharma clients.
•Central lab services are performed by hospital labs conducting the trial or are outsourced to CROs. CROs in Argentina and Mexico usually send the samples to be analyzed abroad. Local outsourcing contracts in LATAM represent about x % of amount spent in outsourced central lab services for in-country conducted trials.

Key Questions this Study will Answer

How will contract research outsourcing help in drug development by saving time and cost for manufacturers?
What is the impact of the market growth in different regions?
Who are the predominant market participants in the CRO market and what is their market share contribution?
What are the key market trends observed towards expansion of contract research organizations in drug development across key therapeutic areas?
Are the products/services offered today meeting customer needs or is additional development needed?
What are the key market segments to look out for and what are the key trends followed in the market?

Table Of Contents

Latin American Contract Research Organization Market : Lower Cost of Conducting Clinical Trials Will Drive Growth
Executive Summary—Latin America 12
• Key Findings—LATAM 13
• Market Size Estimation Methodology 19
• Scope and Segmentation 20
• Key Questions This Study Will Answer 21
• Market Engineering Measurements—LATAM 22
• CEO's Perspective 23
• Key Companies to Watch 24
• 3 Big Predictions 25
Market Overview—Latin America 26
• Market Perspective—LATAM 27
• CRO Market Landscape—LATAM 28
• CRO Market Attractiveness by Phase—LATAM 29
• Porter's Five Forces Analysis for the LATAM CRO Market 30
• CRO Product Development and Commercialization 31
• Market Segmentation—By Stages of Clinical Development 32
Country Breakdown—Argentina -
Market Overview—Argentina 33
• Key Findings—Argentina 34
• Pharmaceutical Market Overview—Argentina 35
• Market Perspective—Argentina 39
• CRO Market Landscape—Argentina 40
Clinical Trials Market Overview—Argentina 41
• Clinical Trials Market Overview—Argentina 42
• Clinical Trials Market Revenue Forecast—Argentina 43
• Total Clinical Trials Market Revenue Forecast Discussion—Argentina 44
• Profiles of Clinical Trials—Argentina 45
• Clinical Trials Scenario—Argentina 47
• Clinical Trials Sponsorship—Argentina 49
Drivers and Restraints—Argentina 50
• Drivers and Restraints—Argentina 51
• Drivers Explained—Argentina 52
• Restraints Explained—Argentina 54
Forecasts and Trends: CRO Market—Argentina 56
• Forecast Assumptions 57
• Market Engineering Measurements—Argentina 58
• Argentina CRO Market—Revenue Forecast 59
• Argentina CRO Market—Revenue Forecast Discussion 60
• CRO Market Snapshot—Argentina 61
• Argentina CRO Market—Phase I and Phase II 62
• Argentina CRO Market—Phase III and Late Phase 63
• Argentina CRO Market—Data Management 64
• Argentina CRO Market—Biostatistics 66
• Argentina CRO Market—Central Laboratory Services 68
• Argentina CRO Market—Health Economics and Outcomes Research (HEOR) 70
• Argentina CRO Market—Pharmacovigilance 72
• Argentina CRO Market—Postmarketing Surveillance 74
• Argentina CRO Market Segmentation—By Stages of Clinical Development 76
• Key Market Trends—Argentina 77
Regulatory Environment—Argentina 78
• Clinical Research Regulatory Overview—Argentina 79
• Clinical Research Regulatory Process—Argentina 80
Competitive Environment—Argentina 83
• Competitive Analysis—Argentina 84
• Market Share Analysis—Argentina 85
• Competitive Structure—Argentina 86
• Competitive Analysis—Selected Key Market Participants 87
Country Breakdown—Brazil -
Market Overview—Brazil 93
• Key Findings—Brazil 94
• Pharmaceutical Market Overview—Brazil 95
• Market Perspective—Brazil 101
• CRO Market Landscape—Brazil 102
Clinical Trials Market Overview—Brazil 103
• Clinical Trials Market Overview—Brazil 104
• Clinical Trials Market Revenue Forecast—Brazil 105
• Clinical Trials Market Revenue Forecast Discussion—Brazil 106
• Profiles of Clinical Trials—Brazil 107
• Clinical Trials Scenario—Brazil 109
• Clinical Trials Sponsorship—Brazil 111
Drivers and Restraints—Brazil 112
• Drivers and Restraints—Brazil 113
• Drivers Explained—Brazil 114
• Restraints Explained—Brazil 117
Forecasts and Trends: CRO Market—Brazil 119
• Forecast Assumptions 120
• Market Engineering Measurements—Brazil 121
• Brazil CRO Market—Revenue Forecast 122
• Brazil CRO Market—Revenue Forecast Discussion 123
• CRO Market Snapshot 124
• Brazil CRO Market—Phase I and Phase II 125
• Brazil CRO Market—Phase III and Late Phase 126
• Brazil CRO Market—Data Management 127
• Brazil CRO Market—Biostatistics 129
• Brazil CRO Market—Central Laboratory Services 131
• Brazil CRO Market—Health Economics and Outcomes Research (HEOR) 133
• Brazil CRO Market—Pharmacovigilance 135
• Brazil CRO Market—Postmarketing Surveillance 137
• Brazil CRO Market Segmentation—By Stages of Clinical Development 139
• Key Market Trends—Brazil 140
Regulatory Environment—Brazil 141
• Clinical Research Regulatory Overview—Brazil 142
• Clinical Research Regulatory Process—Brazil 145
Competitive Environment—Brazil 146
• Competitive Analysis—Brazil 147
• Market Share Analysis—Brazil 148
• Competitive Structure—Brazil 149
• Competitive Analysis—Selected Key Market Participants 150
Country Breakdown—Mexico -
Market Overview—Mexico 157
• Key Findings—Mexico 158
• Pharmaceutical Market Overview—Mexico 159
• Market Perspective—Mexico 164
• CRO Market Landscape—Mexico 165
Clinical Trials Market Overview—Mexico 166
• Clinical Trials Market Overview—Mexico 167
• Clinical Trials Market Revenue Forecast—Mexico 168
• Clinical Trials Market Revenue Forecast Discussion—Mexico 169
• Profiles of Clinical Trials—Mexico 170
• Clinical Trials Scenario—Mexico 172
• Clinical Trials Sponsorship—Mexico 174
Drivers and Restraints—Mexico 175
• Drivers and Restraints—Mexico 176
• Drivers Explained—Mexico 177
• Restraints Explained—Mexico 179
Forecasts and Trends: CRO Market—Mexico 181
• Forecast Assumptions 182
• Market Engineering Measurements—Mexico 183
• Mexico CRO Market—Revenue Forecast 184
• Mexico CRO Market—Revenue Forecast Discussion 185
• CRO Market Snapshot—Mexico 186
• Mexico CRO Market—Phase I and Phase II 187
• Mexico CRO Market—Phase III and Late Phase 188
• Mexico CRO Market—Data Management 189
• Mexico CRO Market—Biostatistics 191
• Mexico CRO Market—Central Laboratory Services 193
• Mexico CRO Market—Health Economics and Outcomes Research (HEOR) 195
• Mexico CRO Market—Pharmacovigilance 197
• Mexico CRO Market—Postmarketing Surveillance 199
• Mexico CRO Market Segmentation—By Stages of Clinical Development 201
• Key Market Trends—Mexico 202
Regulatory Environment—Mexico 203
• Clinical Research Regulatory Overview—Mexico 204
• Clinical Research Regulatory Process—Mexico 207
Competitive Environment—Mexico 208
• Competitive Analysis—Mexico 209
• Market Share Analysis—Mexico 210
• Competitive Structure—Mexico 211
• Competitive Analysis—Selected Key Market Participants 212
The Last Word 219
• 3 Big Predictions 220
• The Last Word - Discussion 221
• Legal Disclaimer 222
Appendix 223
• List of Exhibits 224



View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Bioinformatics Market by Sector (Molecular Medicine, Agriculture, Forensic, Animal, Research & Gene Therapy), Product (Sequencing Platforms, Knowledge Management & Data Analysis) & Application (Genomics, Proteomics & Metabolomics) - Global Forecast to 202

Bioinformatics Market by Sector (Molecular Medicine, Agriculture, Forensic, Animal, Research & Gene Therapy), Product (Sequencing Platforms, Knowledge Management & Data Analysis) & Application (Genomics, Proteomics & Metabolomics) - Global Forecast to 202

  • $ 5650
  • Industry report
  • October 2016
  • by MarketsandMarkets

The global bioinformatics market is projected to reach USD 16.18 billion by 2021 from USD 6.21 billion in 2016, growing at a CAGR of 21.1% during the forecast period. In this report, the bioinformatics ...

Clinical Trial Management System Market by End-user, Delivery Mode, Type, Component - Global Forecast to 2021

Clinical Trial Management System Market by End-user, Delivery Mode, Type, Component - Global Forecast to 2021

  • $ 5650
  • Industry report
  • August 2016
  • by MarketsandMarkets

The global clinical trial management system (CTMS) market is estimated to grow at a CAGR of 11.5% from 2016 to 2021, to reach USD 920.0 billion by 2021. The adoption of CTMS software is on the rise across ...

Contract Research Organizations Services Market by Type, Therapeutic Area, End User - Global Forecast to 2021

Contract Research Organizations Services Market by Type, Therapeutic Area, End User - Global Forecast to 2021

  • $ 5650
  • Industry report
  • October 2016
  • by MarketsandMarkets

The global CRO services market is estimated to grow at a CAGR of 7.4% from 2016 to 2021, to reach USD 41.86 billion by 2021 from USD 29.29 billion in 2016. Growth in this market is primarily attributed ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.